Gilead and CV Therapeutics: What the Pundits Are Saying

“Another deal believe it or not in the drug industry has just come down. This time Gilead Sciences is buying CV Therapeutics, a $1.4 billion deal. We’ve seen so many acquisitions including Genentech-Roche which we talked about happening in recent days. $1.4 billion for CV Therapeutics which works out to $20 a share in cash.” [...]